Nkarta, Inc. (NKTX)
NASDAQ: NKTX · Real-Time Price · USD
1.980
-0.030 (-1.49%)
Aug 8, 2025, 4:00 PM - Market closed
Company Description
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment.
The company’s lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.
It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Nkarta, Inc.
| Country | United States |
| Founded | 2015 |
| IPO Date | Jul 10, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 157 |
| CEO | Paul Hastings |
Contact Details
Address: 1150 Veterans Boulevard South San Francisco, California 94080 United States | |
| Phone | 925 407 1049 |
| Website | nkartatx.com |
Stock Details
| Ticker Symbol | NKTX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001787400 |
| CUSIP Number | 65487U108 |
| ISIN Number | US65487U1088 |
| Employer ID | 47-4515206 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Paul J. Hastings | Chief Executive Officer and Director |
| Dr. Nadir Mahmood Ph.D. | President and Principal Accounting and Financial Officer |
| Greg Mann | Vice President of Public Affairs and Investor Relations |
| Dr. Shawn Rose M.D., Ph.D. | Chief Medical Officer and Head of Research and Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 6, 2025 | 8-K | Current Report |
| May 14, 2025 | 10-Q | Quarterly Report |
| May 14, 2025 | 8-K | Current Report |
| Apr 21, 2025 | ARS | Filing |
| Apr 21, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 21, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 26, 2025 | 10-K | Annual Report |
| Mar 26, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 12, 2025 | SCHEDULE 13D/A | Filing |